CAR t therapy takes on lupus and other autoimmune diseases
NCT ID NCT06462144
First seen Feb 01, 2026 · Last updated May 08, 2026 · Updated 11 times
Summary
This early-phase trial tested a single dose of IMPT-514, a personalized CAR T cell therapy, in 3 adults with active, treatment-resistant lupus, vasculitis, or inflammatory myopathy. The main goal was to check safety and side effects. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS (AAV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital Of Xuzhou Medical University
Xuzhou, Jiangsu, 221004, China
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jiangsu, 210008, China
-
Zhongshan Hospital Fudan University.
Shanghai, Shanghai Municipality, 200032, China
Conditions
Explore the condition pages connected to this study.